Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report released on Saturday. The brokerage set a “hold” rating on the stock.

Several other equities research analysts have also recently commented on ONCT. Brookline Capital Management restated a “hold” rating on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Northland Capmk downgraded shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 12th. Finally, Northland Securities reaffirmed a “market perform” rating and issued a $2.00 target price on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, Oncternal Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $10.00.

Oncternal Therapeutics Price Performance

ONCT opened at $0.53 on Friday. Oncternal Therapeutics has a 52 week low of $0.53 and a 52 week high of $13.14. The business has a 50 day moving average price of $1.06 and a two-hundred day moving average price of $3.75. The company has a market cap of $1.56 million, a PE ratio of -0.05 and a beta of 1.18.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.